GoodRx Holdings, Inc. (GDRX) Stock Price & Analysis
GoodRx Holdings, Inc. (GDRX) closed at USD 3.62 on Thursday, October 22, 2026, up 1.40% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 3.57; the Oct 22, 2026 session ranged USD 3.55–3.64 on volume of 725,329 shares. Market capitalization is $1.23B, with a 52-week range of USD 1.77–4.05 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:12 UTC.
Also available as compact Markdown for AI agents: nexqual.com/GDRX.md
Key facts (GDRX)
- Last four reported quarters (through Jun 30, 2026): revenue $785M, net income $16.2M (2.1% margin), free cash flow $197M (SEC filings).
- Valuation: P/E 76.0x (avg 71.5x at the last 2 fiscal year-ends), EV/EBITDA 8.7x, net debt $190M.
- Earnings quality: non-operating income -$33.5M vs operating income $74.9M over the last four quarters; P/E excluding non-operating income ≈32.5x (estimate: non-operating income taxed at the company's 35% effective rate).
- Analysts: Hold (mean 2.93 on a 1–5 scale) (14 analysts), mean target USD 3.95 (range 2.65–5).
- Total return with dividends: 1Y -6.2% vs S&P 500 +14.9%; 5Y -92.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-03, EPS estimate USD 0.08, revenue estimate $202M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (GDRX)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $745M | $767M | $750M | $792M | $797M | $785M |
| Operating income | $13.4M | $1.7M | -$27.0M | $65.8M | $87.5M | $74.9M |
| Net income | -$25.3M | -$32.8M | -$8.9M | $16.4M | $30.4M | $16.2M |
| EPS (diluted) | -$0.06 | -$0.08 | -$0.02 | $0.04 | $0.09 | — |
| Free cash flow | $174M | $143M | $137M | $183M | $164M | $197M |
| Operating margin | 1.8% | 0.2% | -3.6% | 8.3% | 11.0% | 9.5% |
| Net margin | -3.4% | -4.3% | -1.2% | 2.1% | 3.8% | 2.1% |
| Revenue growth | +35.4% | +2.8% | -2.1% | +5.6% | +0.6% | — |
| Cash + short-term investments | $941M | $757M | $672M | $448M | $262M | — |
| Total debt | $674M | $667M | $656M | $500M | $495M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (GDRX)
P/E 76.0x · P/E ex non-operating (est.) ≈32.5x · P/S 1.6x · EV/EBITDA 8.7x · EV/Sales 1.8x · P/FCF 6.3x · P/B 1.9x · FCF yield 15.96% · Earnings yield 1.32% · Buyback yield (TTM) 6.88% · Net debt $190M · EV $1.43B
P/E at fiscal year-ends: Dec 2025 31.8x, Dec 2024 111.3x.
Analysts (GDRX)
Consensus Hold (mean 2.93 on a 1–5 scale), 14 analysts; mean target USD 3.95 (low 2.65, high 5).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-21 | Barclays | Target raised | Underweight | $3 → $4 |
| 2026-08-13 | UBS | Target raised | Neutral | $2.5 → $3.75 |
| 2026-08-11 | Citigroup | Target raised | Buy | $4 → $5 |
| 2026-08-11 | TD Cowen | Target raised | Buy | $4 → $5 |
| 2026-08-07 | Wells Fargo | Target raised | Overweight | $3.5 → $5 |
Total return (dividends reinvested) (GDRX)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -6.2% | -92.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -6.2% | -40.1% |
| Volatility (annualized) | 56.1% | 72.0% |
| Max drawdown | -52.7% (Oct 2025→Feb 2026) | -96.0% (Oct 2021→Feb 2026) |
GDRX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.08 | $0.08 | -2.3% | $202.1M | 11 |
| Next quarter (ends Dec 2026) | $0.08 | $0.08 | -5.1% | $202.1M | 11 |
| Current fiscal year (ends Dec 2026) | $0.30 | $0.31 | -1.9% | $798.5M | 11 |
| Next fiscal year (ends Dec 2027) | $0.35 | $0.36 | -1.7% | $836.2M | 11 |
Key Statistics (as of October 23, 2026 at 10:12 UTC)
| Price | USD 3.62 |
|---|---|
| Change | ▲ 1.40% (up) |
| Previous Close | USD 3.57 |
| Open | USD 3.55 |
| Day Range | USD 3.55 – 3.64 |
| 52-Week Range | USD 1.77 – 4.05 |
| Volume | 725,329 shares |
| Market Cap | $1.23B |
| Exchange | NMS |
Technical Analysis (GDRX)
Nexqual's technical model rates GDRX "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 10:12 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.47 (neutral) |
| vs SMA50 | Above (USD 3.45) |
| MACD | 0.04 (positive) |
Analyst Ratings (GDRX)
Wall Street analysts rate GDRX "Hold" based on 14 analysts, with a mean price target of USD 3.95 (range USD 2.65–5), per Nexqual as of October 23, 2026 at 10:12 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 3.95 |
| High Target | USD 5 |
| Low Target | USD 2.65 |
| Buy / Hold / Sell | 4 / 8 / 2 |
Earnings (GDRX)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD 0.08 |
| Revenue Estimate | $202.09M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.08 vs est 0.08 ▲ beat |
| 2026-03-31 | USD 0.07 vs est 0.07 ▼ miss |
| 2025-12-31 | USD 0.09 vs est 0.09 ▼ miss |
| 2025-09-30 | USD 0.08 vs est 0.09 ▼ miss |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financials & Fundamentals (GDRX)
| Total Revenue | $785.23M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -1.30% |
| Gross Margin | +90.83% |
| Operating Margin | +11.79% |
| Profit Margin | +2.07% |
| ROE | +2.52% |
| Debt / Equity | 0.83 |
| Current Ratio | 1.38 |
| Total Cash | $296.11M |
| Total Debt | $538.95M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $197.09M (25.1% of revenue) |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Financial Health Score (GDRX)
Nexqual rates GoodRx Holdings, Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 10:12 UTC.
| Growth | Mixed — Revenue +0.6% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 91%, operating 12% (last 12 months) |
| Balance Sheet | Mixed — $296M cash and investments vs $487M debt (Jun 2026, SEC) |
| Cash Flow | Strong — FCF $197M (last 4 quarters to Jun 2026, SEC), 25% margin |
| Efficiency | Weak — ROE 3%, ROA 3.0% |
Ownership (GDRX)
| Insider Ownership | +12.88% |
|---|---|
| Institutional Ownership | +55.69% |
| Shares Outstanding | 107.18M |
| Float | 93.79M |
| Short % of Float | +4.34% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Leadership (GDRX)
GoodRx Holdings, Inc. is led by Wendy Barnes, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:12 UTC.
| President, CEO & Director | Wendy Barnes |
|---|---|
| Co-founder & Director | Douglas Joseph Hirsch |
| Chief Strategy & Operations Officer, CFO and Treasurer | Justin Fengler |
| Chief Technology Officer | Nitin Shingate |
| Director of Investor Relations | Aubrey Reynolds |
Major Backers & Investors (GDRX)
Notable institutional backers of GoodRx Holdings, Inc. include LSV Asset Management, Ameriprise Financial, Inc., Silver Lake Group, LLC, according to Nexqual as of October 23, 2026 at 10:12 UTC.
Active Investors
| Investor | Stake |
|---|---|
| LSV Asset Management | 4.92% |
| Ameriprise Financial, Inc. | 4.53% |
| Silver Lake Group, LLC | 3.37% |
| Renaissance Technologies | 3.1% |
| Petrus Trust Company, LTA | 2.96% |
| AQR Capital Management, LLC | 2.22% |
| DFA INVESTMENT DIMENSIONS GROUP INC-U.S. Small Cap Value Portfolio | 0.53% |
| Fidelity | 0.46% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.96% |
| Dimensional Fund Advisors | 2.45% |
Source: Nexqual, October 23, 2026 at 10:12 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OMDA | Omada Health, Inc. | USD 18.98 | ▼ 3.46% |
| TDOC | Teladoc Health, Inc. | USD 6.32 | ▲ 0.32% |
| HSTM | HealthStream, Inc. | USD 34.59 | ▲ 3.22% |
| CERT | Certara, Inc. | USD 10.09 | ▼ 0.88% |
| OMCL | Omnicell, Inc. | USD 37.1 | ▲ 2.09% |
| SDGR | Schrodinger, Inc. | USD 22.6 | ▼ 5.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:12 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt